NSE close · Fri, 25 SeptNifty 5023,140.50▲ 0.34%Nifty Bank55,580.40▲ 0.26%Midcap 10060,906.00▼ 0.14%Smallcap 25018,158.900.02%India VIX12.16▼ 4.18%IT28,160.90▼ 0.17%Auto26,967.90▲ 0.89%Pharma27,003.00▼ 0.10%FMCG45,941.30▲ 0.40%Metal13,087.15▲ 0.35%Realty869.35▲ 0.92%Energy37,440.35▲ 0.21%PSU Bank8,294.50▲ 0.28%Financials25,094.85▲ 0.56%Media1,550.65▼ 0.23%Defence9,401.65▲ 0.43%Durables38,278.60▲ 0.95%Biggest movesTURTLEMINT▼ 20.0%ADSL▲ 20.0%HEROMOTORS▲ 20.0%SHANTIGOLD▲ 14.8%UGARSUGAR▲ 14.8%MAWANASUG▲ 14.5%TGVSL▲ 14.2%UTTAMSUGAR▲ 12.7%

Top stories

Picking up + Pharma and healthcare · 1 storyClear filters

Developing 74 Picking up 33 Price moves 1 Following

Busiest tags today

Market valuations80 Geopolitics75 Global markets71 Banks69 Crude oil66 AI59 Nifty and Sensex57 Iran49 Donald Trump38 Gold34 Bond yields32 Stock exchanges27 China26 Trade and tariffs26 Every tag in Market pulse →

Topic

Pharma and healthcare● −7% net tone today

19 stories today · 57 since 24 SeptNifty Pharma −0.10% vs Nifty +0.34% on Fri, 25 Sept

Sun Pharma secured exclusive worldwide rights to Lerodalcibib, excluding the US and China
Morepen Laboratories submitted its first ANDA to USFDA for Sitagliptin Tablets
Dr Reddy's shares gained over 1% after Nomura retained its Buy rating

Often with, this weekHospitals9 USFDA7 Eli Lilly4 Novo Nordisk4 Fortis Healthcare3

Open tag page →Clear ×

Stories per day

1124 Sept

2125 Sept

726 Sept

527 Sept

1328 Sept

Deal▲Picking up

Sun Pharma signs exclusive licensing agreement with LIB Therapeutics Inc.

Sun Pharma secured exclusive rights to commercialize and manufacture Lerodalcibep worldwide, excluding the US and China
The licensing deal gives Sun Pharma a potential global product opportunity outside the US and China

Sun Pharma Pharma and healthcare China2 sources · 42m

That’s everything for today